ASLAN Pharmaceuticals (NASDAQ:ASLN) Earns “Buy” Rating from HC Wainwright

ASLAN Pharmaceuticals (NASDAQ:ASLN)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a report released on Tuesday, Benzinga reports. They currently have a $9.00 price objective on the stock.

Separately, Piper Sandler reaffirmed an “overweight” rating and issued a $10.00 target price (down previously from $15.00) on shares of ASLAN Pharmaceuticals in a research report on Wednesday, March 13th.

ASLAN Pharmaceuticals Stock Performance

Shares of ASLN stock opened at $0.47 on Tuesday. The company’s 50-day moving average price is $0.61 and its 200-day moving average price is $0.72. The stock has a market cap of $7.68 million, a price-to-earnings ratio of -0.17 and a beta of 1.45. ASLAN Pharmaceuticals has a twelve month low of $0.39 and a twelve month high of $4.69.

ASLAN Pharmaceuticals (NASDAQ:ASLN) last announced its quarterly earnings results on Friday, April 12th. The company reported ($0.78) earnings per share for the quarter. As a group, equities research analysts predict that ASLAN Pharmaceuticals will post -2.68 EPS for the current year.

ASLAN Pharmaceuticals Company Profile

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal antibody that targets the IL-13 receptor a1 subunit which is being developed for the treatment of atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune diseases.